---
title: "AstraZeneca (United Kingdom): research papers"
description: "From 2017 to 2026 (so far), authors at AstraZeneca (United Kingdom) took part in 46 papers in the tracked journals, most of them in health economics and policy (22), AI (13) and statistics (10). 5 of them were published in 2025, against 2 in 2017."
url: https://scholar4ai.com/companies/astrazeneca-united-kingdom
markdown_url: https://scholar4ai.com/companies/astrazeneca-united-kingdom.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at AstraZeneca (United Kingdom) took part in 46 papers in the tracked journals, most of them in health economics and policy (22), AI (13) and statistics (10). 5 of them were published… (as of 2026-11-05)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-11-05T06:02:37+09:00
window: 2026-10-07 to 2026-11-05
source: OpenAlex (CC0)
---

# AstraZeneca (United Kingdom)

[Browse company research profiles](https://scholar4ai.com/companies/directory.md)

Papers in the tracked journals with an author at AstraZeneca (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at AstraZeneca (United Kingdom) took part in 46 papers in the tracked journals, most of them in health economics and policy (22), AI (13) and statistics (10).
- 5 of them were published in 2025, against 2 in 2017.
- Since 2023, the institutions with the most of these papers were AstraZeneca (Sweden) (7), University of Leicester (5) and University of Cambridge (4).
- The journals publishing most of them were Nature Machine Intelligence (5), BMC Medical Research Methodology (4) and PharmacoEconomics - Open (4).
- The most-cited of them is “Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans” (Nature Machine Intelligence, 2021), with 1,045 citations.
- Since 2023, papers in the tracked journals cited 14 of its papers 71 times; 96% of those links came from papers with a university author and 3% from its own papers.
- Its own papers since 2023 cite archived papers 33 times, 39% of them papers with a company author.
- Across everything OpenAlex indexes, AstraZeneca (United Kingdom) has 18,858 works with 2,519,474 citations (h-index 552).
- The tracked journals hold 37 of its 9,981 works in OpenAlex from 2017 to 2025 (0.4%).
- Its main research topics in OpenAlex are Asthma and respiratory diseases (1,416), Lung Cancer Treatments and Mutations (1,334) and Chronic Obstructive Pulmonary Disease (COPD) Research (1,227).

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 2 | 0 | 1 | 3 | 1 | 3 | 3 | 4 | 2 | 3 |
| [AI](https://scholar4ai.com/categories/ai.md) | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 4 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 2 | 2 | 2 |
| [Management](https://scholar4ai.com/categories/management.md) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| All categories | 2 | 0 | 3 | 5 | 3 | 7 | 5 | 7 | 5 | 9 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 5 |
| 2 | [BMC Medical Research Methodology](https://scholar4ai.com/journals/bmc-medical-research-methodology.md) | 4 |
| 3 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 4 |
| 4 | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 3 |
| 5 | [Health and Quality of Life Outcomes](https://scholar4ai.com/journals/health-and-quality-of-life-outcomes.md) | 2 |
| 6 | [Technological Forecasting and Social Change](https://scholar4ai.com/journals/technological-forecasting-and-social-change.md) | 1 |
| 7 | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 1 |
| 8 | [Knowledge-Based Systems](https://scholar4ai.com/journals/knowledge-based-systems.md) | 1 |
| 9 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 1 |
| 10 | [Patient](https://scholar4ai.com/journals/patient.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | [AstraZeneca (Sweden)](https://scholar4ai.com/companies/astrazeneca-sweden.md) | 7 |
| 2 | University of Leicester | 5 |
| 3 | [University of Cambridge](https://scholar4ai.com/institutions/university-of-cambridge.md) | 4 |
| 4 | AstraZeneca (United States) | 3 |
| 5 | University Medical Center Groningen | 3 |
| 6 | [University of Groningen](https://scholar4ai.com/institutions/university-of-groningen.md) | 3 |
| 7 | AstraZeneca (Canada) | 2 |
| 8 | AstraZeneca (Spain) | 2 |
| 9 | [Health Economics and Outcomes Research (United Kingdom)](https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom.md) | 2 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United Kingdom | 26 |
| 2 | Sweden | 9 |
| 3 | United States | 5 |
| 4 | Australia | 4 |
| 5 | Germany | 4 |
| 6 | Canada | 3 |
| 7 | China | 3 |
| 8 | Netherlands | 3 |
| 9 | Brazil | 2 |
| 10 | Egypt | 2 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 5 |
| 2 | [quality-adjusted life years](https://scholar4ai.com/keywords/quality-adjusted-life-years.md) | 4 |
| 3 | adjuvant therapy | 3 |
| 4 | incremental cost-effectiveness ratio | 3 |
| 5 | cancer clinical trials | 2 |
| 6 | chronic kidney disease | 2 |
| 7 | [cross-national comparison](https://scholar4ai.com/keywords/cross-national-comparison.md) | 2 |
| 8 | denoising diffusion probabilistic models | 2 |
| 9 | early breast cancer | 2 |
| 10 | [health technology assessment](https://scholar4ai.com/keywords/health-technology-assessment.md) | 2 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 1,045 | 15.4 | [Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans](https://doi.org/10.1038/s42256-021-00307-0) | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 2021-03-15 | Michael Roberts, Derek Driggs, Matthew Thorpe et al. |
| 2 | 152 | 2.6 | [Data harmonisation for information fusion in digital healthcare: A state-of-the-art systematic review, meta-analysis and future research directions](https://doi.org/10.1016/j.inffus.2022.01.001) | [Information Fusion](https://scholar4ai.com/journals/information-fusion.md) | 2022-01-24 | Nan Yang, Javier Del Ser, Simon L. F. Walsh et al. |
| 3 | 131 | 3.1 | [Game changers in science and technology - now and beyond](https://doi.org/10.1016/j.techfore.2023.122588) | [Technological Forecasting and Social Change](https://scholar4ai.com/journals/technological-forecasting-and-social-change.md) | 2023-05-04 | Ulrich A. K. Betz, Loukik Arora, R.A. Assal et al. |
| 4 | 75 | 1.3 | [Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence](https://doi.org/10.1038/s42256-021-00421-z) | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 2021-12-15 | Xiang Bai, Hanchen Wang, Liya Ma et al. |
| 5 | 24 | 0.3 | [Efficient feature selection using shrinkage estimators](https://doi.org/10.1007/s10994-019-05795-1) | [Machine Learning](https://scholar4ai.com/journals/machine-learning.md) | 2019-05-09 | Konstantinos Sechidis, Laura Azzimonti, Adam Pocock et al. |
| 6 | 15 | 0.3 | [Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer](https://doi.org/10.1007/s41669-023-00396-0) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2023-02-22 | Andre Verhoek, Parneet Kaur Cheema, Barbara L. Melosky et al. |
| 7 | 13 | 0.1 | [Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden](https://doi.org/10.1007/s41669-017-0031-6) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2017-06-01 | Ugne Sabale, Mattias Ekman, Daniel Thunström et al. |
| 8 | 13 | 0.8 | [Statistical Perspectives on Reproducibility: Definitions and Challenges](https://doi.org/10.1007/s42519-025-00459-x) | [Journal of Statistical Theory and Practice](https://scholar4ai.com/journals/journal-of-statistical-theory-and-practice.md) | 2025-05-27 | Andrea Simkus, Tahani Coolen‐Maturi, Frank P. A. Coolen et al. |
| 9 | 13 | 0.8 | [Mask-prior-guided denoising diffusion improves inverse protein folding](https://doi.org/10.1038/s42256-025-01042-6) | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 2025-06-16 | Peizhen Bai, Filip N. Miljković, Xianyuan Liu et al. |
| 10 | 12 | 0.2 | [Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer](https://doi.org/10.1007/s41669-022-00338-2) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2022-08-29 | David Elsea, Lin Fan, Adela Mihai et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | [University of Cambridge](https://scholar4ai.com/institutions/university-of-cambridge.md) | University | United Kingdom | 8 |
| 2 | [Imperial College London](https://scholar4ai.com/institutions/imperial-college-london.md) | University | United Kingdom | 7 |
| 3 | The Alan Turing Institute | Research facility | United Kingdom | 5 |
| 4 | [King's College London](https://scholar4ai.com/institutions/king-s-college-london.md) | University | United Kingdom | 4 |
| 5 | [University of Manchester](https://scholar4ai.com/institutions/university-of-manchester.md) | University | United Kingdom | 3 |
| 6 | [University of Oxford](https://scholar4ai.com/institutions/university-of-oxford.md) | University | United Kingdom | 3 |
| 7 | Royal Brompton Hospital | Healthcare | United Kingdom | 3 |
| 8 | Tecnalia | Other | Spain | 3 |
| 9 | [University College London](https://scholar4ai.com/institutions/university-college-london.md) | University | United Kingdom | 3 |
| 10 | [Indian Statistical Institute](https://scholar4ai.com/institutions/indian-statistical-institute.md) | University | India | 3 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | [Durham University](https://scholar4ai.com/institutions/durham-university.md) | University | United Kingdom | 5 |
| 2 | [Bristol-Myers Squibb (United Kingdom)](https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom.md) | Company | United Kingdom | 3 |
| 3 | Portland State University | University | United States | 2 |
| 4 | [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states.md) | Company | United States | 2 |
| 5 | Merck KGaA, Darmstadt (Germany) | Company | Germany | 2 |
| 6 | [Chinese Academy of Sciences](https://scholar4ai.com/institutions/chinese-academy-of-sciences.md) | Government | China | 2 |
| 7 | [University of Manchester](https://scholar4ai.com/institutions/university-of-manchester.md) | University | United Kingdom | 2 |
| 8 | [Bristol-Myers Squibb (United States)](https://scholar4ai.com/companies/bristol-myers-squibb-united-states.md) | Company | United States | 2 |
| 9 | [Health Economics and Outcomes Research (United Kingdom)](https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom.md) | Company | United Kingdom | 2 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## In OpenAlex

*AstraZeneca (United Kingdom) in OpenAlex*

| Item | Value |
|---|---|
| Type | Company |
| Location | Cambridge, England, United Kingdom |
| Units listed in OpenAlex | 18 |
| Works in OpenAlex | 18,858 |
| Citations | 2,519,474 |
| h-index | 552 |
| i10-index | 26,537 |
| 2-year mean citedness | 8.17 |
| Website | [www.astrazeneca.com](https://www.astrazeneca.com) |
| ROR | [ror.org/04r9x1a08](https://ror.org/04r9x1a08) |
| OpenAlex | [openalex.org/I105036370](https://openalex.org/I105036370) |

*Works and citations per year in OpenAlex, and its papers in the tracked journals*

| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---:|---:|---:|---:|
| 2026 (so far) | 1,131 | 69,470 | 9 | 0.8% |
| 2025 | 1,552 | 83,542 | 5 | 0.3% |
| 2024 | 1,442 | 79,805 | 7 | 0.5% |
| 2023 | 1,367 | 72,909 | 5 | 0.4% |
| 2022 | 1,123 | 69,893 | 7 | 0.6% |
| 2021 | 1,102 | 68,049 | 3 | 0.3% |
| 2020 | 1,025 | 52,643 | 5 | 0.5% |
| 2019 | 879 | 41,737 | 3 | 0.3% |
| 2018 | 793 | 36,545 | 0 | 0.0% |
| 2017 | 698 | 33,068 | 2 | 0.3% |

*Main research topics (OpenAlex, all works)*

| # | Topic | Field | Works |
|---:|---|---|---:|
| 1 | Asthma and respiratory diseases | Medicine | 1,416 |
| 2 | Lung Cancer Treatments and Mutations | Medicine | 1,334 |
| 3 | Chronic Obstructive Pulmonary Disease (COPD) Research | Medicine | 1,227 |
| 4 | Computational Drug Discovery Methods | Computer Science | 1,062 |
| 5 | Cancer Immunotherapy and Biomarkers | Medicine | 951 |

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

## Cite this page

Scholar4AI. (2026). AstraZeneca (United Kingdom). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/astrazeneca-united-kingdom

```bibtex
@misc{scholar4ai-companies-astrazeneca-united-kingdom,
  author = {{Scholar4AI}},
  title = {AstraZeneca (United Kingdom)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/astrazeneca-united-kingdom}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).